Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 2, Number 4—October 1996

Synopsis

New Vaccines for the Prevention of Pneumococcal Infections

Helena KäyhtyComments to Author  and Juhani Eskola
Author affiliations: National Public Health Institute, Helsinki, Finland

Main Article

Table 1

Pneumococcal conjugate vaccines in phase-II and phase-III trials

Vaccine Serotype Carrier Manufacturer
PncCRM 4, 6B, 9V, 14, 18C, 19F, 23F CRM197 Wyeth-Lederle Vaccines and Pediatrics
PncD 3, 4, 6B, 9V, 14, 18C, 19F, 23 Diphtheria toxoid Connaught Laboratories
PncT 3, 4, 6B, 9V, 14, 18C, 19F, 23 Tetanus toxoid Pasteur Merieux Serums & Vaccins
PncOMPC 4, 6B, 9V, 14, 18C, 19F, 23F Meningococcal OMPC Merck Research Laboratories

CRM = CRM197, a nontoxic variant of diphtheria toxin; D = diphtheria toxoid; T = tetanus toxoid; OMPC = outer membrane protein complex

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO